Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
HOUSTON, Nov. 08, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15 at 9:20 a.m. GMT in London, UK.
A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including allogeneic hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, CFO
832-384-1116
[email protected]
Media:
BMC Communications
Brad Miles
646-513-3125
[email protected]
Source: Bellicum Pharmaceuticals
